181 related articles for article (PubMed ID: 30397685)
1. Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device-induced acquired von Willebrand syndrome.
Deconinck S; Tersteeg C; Bailleul E; Delrue L; Vandeputte N; Pareyn I; Itzhar-Baikian N; Deckmyn H; De Meyer SF; Vanderheyden M; Vanhoorelbeke K
Res Pract Thromb Haemost; 2018 Oct; 2(4):762-766. PubMed ID: 30397685
[TBL] [Abstract][Full Text] [Related]
2. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.
Rauch A; Caron C; Vincent F; Jeanpierre E; Ternisien C; Boisseau P; Zawadzki C; Fressinaud E; Borel-Derlon A; Hermoire S; Paris C; Lavenu-Bombled C; Veyradier A; Ung A; Vincentelli A; van Belle E; Lenting PJ; Goudemand J; Susen S
Thromb Haemost; 2016 May; 115(5):950-9. PubMed ID: 26791163
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of von Willebrand factor profiles after implantation of left ventricular assist device and total artificial heart.
Reich HJ; Morgan J; Arabia F; Czer L; Moriguchi J; Ramzy D; Esmailian F; Lam L; Dunhill J; Volod O
J Thromb Haemost; 2017 Aug; 15(8):1620-1624. PubMed ID: 28586149
[TBL] [Abstract][Full Text] [Related]
4. Detection of acquired von Willebrand syndrome after ventricular assist device by total thrombus-formation analysis system.
Takashio S; Kaikita K; Nishi M; Morioka M; Higo T; Shiose A; Doman T; Horiuchi H; Fukui T; Tsujita K
ESC Heart Fail; 2020 Oct; 7(5):3235-3239. PubMed ID: 32700467
[TBL] [Abstract][Full Text] [Related]
5. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
6. Acquired Von Willebrand syndrome in patients on long-term support with HeartMate II.
Heilmann C; Trummer G; Beyersdorf F; Brehm K; Berchtold-Herz M; Schelling J; Geisen U; Zieger B
Eur J Cardiothorac Surg; 2017 Mar; 51(3):587-590. PubMed ID: 28082469
[TBL] [Abstract][Full Text] [Related]
7. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
[TBL] [Abstract][Full Text] [Related]
9. Acquired Von Willebrand syndrome is an early-onset problem in ventricular assist device patients.
Heilmann C; Geisen U; Beyersdorf F; Nakamura L; Trummer G; Berchtold-Herz M; Schlensak C; Zieger B
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1328-33; discussion 1233. PubMed ID: 21515067
[TBL] [Abstract][Full Text] [Related]
10. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
11. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
[TBL] [Abstract][Full Text] [Related]
12. Comparative assessment of von Willebrand factor multimers vs activity for von Willebrand disease using modern contemporary methodologies.
Favaloro EJ; Oliver S; Mohammed S; Vong R
Haemophilia; 2020 May; 26(3):503-512. PubMed ID: 32159272
[TBL] [Abstract][Full Text] [Related]
13. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
[TBL] [Abstract][Full Text] [Related]
14. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay.
Riddell AF; Jenkins PV; Nitu-Whalley IC; McCraw AH; Lee CA; Brown SA
Br J Haematol; 2002 Jan; 116(1):187-92. PubMed ID: 11841416
[TBL] [Abstract][Full Text] [Related]
15. Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor.
Batsuli G; Zimowski KL; Carroll R; White MH; Woods GM; Meeks SL; Sidonio RF
J Cardiothorac Vasc Anesth; 2022 Mar; 36(3):724-727. PubMed ID: 33618961
[TBL] [Abstract][Full Text] [Related]
16. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
Michiels JJ; van Vliet HH
Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
[TBL] [Abstract][Full Text] [Related]
17. Establishing a method for in vitro investigation of mechanical parameters causing acquired von Willebrand syndrome in ventricular assist devices.
Egger C; Maas J; Hufen T; Schmitz-Rode T; Steinseifer U
Artif Organs; 2013 Sep; 37(9):833-9. PubMed ID: 23834027
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.
Tiede A; Priesack J; Werwitzke S; Bohlmann K; Oortwijn B; Lenting P; Eisert R; Ganser A; Budde U
J Thromb Haemost; 2008 Apr; 6(4):569-76. PubMed ID: 18208537
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
20. Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS).
Heilmann C; Geisen U; Beyersdorf F; Nakamura L; Benk C; Trummer G; Berchtold-Herz M; Schlensak C; Zieger B
Intensive Care Med; 2012 Jan; 38(1):62-8. PubMed ID: 21965100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
